Genocea Biosciences Inc. (GNCA) 11.08 $GNCA
Virology Publishes Genocea HSV-2 Antigen Discovery Paper
Business Wire - Tue Sep 16, 8:02AM CDT
Genocea Biosciences, Inc. (NASDAQ: GNCA), a clinical-stage biopharmaceutical company developing T cell-directed vaccines and immunotherapies, today announced that the peer-reviewed journal Virology has published a paper describing how Genocea used it's ATLAS(TM) platform to identify the herpes simplex virus 2 (HSV-2) antigens for its GEN-003 clinical program. The paper, titled "Identification of novel virus-specific antigens by CD4+ and CD8+ T cells from asymptomatic HSV-2 seropositive and seronegative donors," positively identified multiple viral antigens that are associated with naturally-induced protective CD4+ and CD8+ T cell responses, presenting possible targets for the development of new immunotherapies and prophylactic vaccines.
Genocea reports launch of Phase 2a trial for universal pneumococcal vaccine candidate GEN-004
M2 - Fri Sep 12, 7:58AM CDT
Biopharmaceutical company Genocea Biosciences (NasdaqGM:GNCA) announced on Thursday that it has started its Phase 2a trial of its universal vaccine candidate against pneumococcus, GEN-004.
Genocea Commences Phase 2a Trial for GEN-004, Universal Pneumococcal Vaccine Candidate
Business Wire - Thu Sep 11, 1:00PM CDT
Genocea Biosciences, Inc. (NASDAQ: GNCA), a clinical-stage biopharmaceutical company developing T cell-directed vaccines and immunotherapies, today announced the initiation of a Phase 2a trial for GEN-004, the Company's universal vaccine candidate against pneumococcus. The trial is designed to evaluate the effect of dosing with GEN-004 on the frequency, magnitude and duration of colonization by pneumococcus in the nasopharynx of healthy adults.
Genocea Appoints Kenneth Bate to its Board of Directors
Business Wire - Thu Sep 11, 11:30AM CDT
Genocea Biosciences, Inc. (NASDAQ: GNCA), a clinical-stage biopharmaceutical company developing T cell-directed vaccines and immunotherapies, today announced that Kenneth Bate has joined the company's board of directors. Mr. Bate will also serve as chairman of the company's Compensation committee and a member of the Audit committee.
Genocea Presents Phase 1 Immunology Data for Novel Pneumoccocus Vaccine at ICAAC
Business Wire - Sat Sep 06, 3:00PM CDT
Genocea Biosciences, Inc. (NASDAQ: GNCA), a biopharmaceutical company developing T cell-directed vaccines and immunotherapies, today presented data from a Phase 1 study of GEN-004, an investigational vaccine designed to prevent disease caused by all serotypes of pneumococcus (Streptococcus pneumoniae) The poster (G-291), titled "Safety and Immunogenicity of a Novel Lipidated Protein Subunit Streptococcus Pneumoniae vaccine," was presented at the 54th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) in Washington, DC.
HSV-2 Vaccine in Development: CBCD Congratulates Genocea Biosciences (GNCA)
PRWeb - Sun Aug 17, 1:46AM CDT
"Infected with HSV-2? The CBCD recommends taking Novirin or Gene-Eden-VIR." - Greg Bennett, CBCD
Genocea Reports Second Quarter 2014 Financial Results
Business Wire - Wed Aug 06, 7:01AM CDT
Genocea Biosciences, Inc. (NASDAQ:GNCA), a clinical-stage biopharmaceutical company developing T cell-enabled vaccines and immunotherapies, today reported recent corporate highlights and its financial results for the second quarter ended June 30, 2014.
Genocea to Announce Second Quarter 2014 Financial Results on August 6, 2014
Business Wire - Wed Jul 30, 7:01AM CDT
Genocea Biosciences, Inc. (NASDAQ:GNCA), a clinical-stage biopharmaceutical company developing T cell-enabled vaccines and immunotherapies, announced today that it will hold a conference call and live audio webcast on August 6, 2014 at 9:00 a.m. ET to discuss financial results for the quarter ended June 30, 2014. The presentation, hosted by Genocea president and chief executive officer Chip Clark and chief financial officer Jonathan Poole, will also provide an update on the company's recent progress and upcoming milestones.
Genocea HSV-2 Immunotherapeutic GEN-003 Elicits Significant, Durable T Cell Responses in Vaccinated Subjects
Business Wire - Tue Jul 22, 7:02AM CDT
Genocea Biosciences, Inc. (NASDAQ:GNCA), a clinical-stage biopharmaceutical company developing T cell-enabled vaccines and immunotherapies, today presented data from a Phase 1/2a study of GEN-003, the Company's investigational immunotherapy against HSV-2, demonstrating that the immunotherapy elicited T cell, IgG and neutralizing antibody responses that remained significantly above baseline for 12 months after treatment. The data were presented at the 39th Annual International Herpesvirus Workshop, being held July 19-23, 2014 in Kobe, Japan.
Genocea Commences Phase 2 Dose Optimization Trial for GEN-003 HSV-2 Immunotherapy
Business Wire - Mon Jul 21, 7:01AM CDT
Genocea Biosciences, Inc. (NASDAQ:GNCA), a clinical-stage biopharmaceutical company developing T cell-enabled vaccines and immunotherapies, today announced the start of a Phase 2 dose optimization trial for GEN-003, the Company's immunotherapy candidate against herpes simplex-type 2 (HSV-2).
Genocea Biosciences, Inc. (GNCA) in Focus: Stock Rises 7.52% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Jul 17, 7:44AM CDT
Genocea Biosciences, Inc. (GNCA) was a big mover last session, as the company saw its shares rise over 7% on the day.
Genocea Biosciences decides not to pursue public offering due to market conditions
M2 - Thu Jul 17, 5:34AM CDT
Biopharmaceutical company Genocea Biosciences (NasdaqGM:GNCA) said on Wednesday that it has elected not to proceed with its plans to pursue its public offering of 3,400,000 shares of its common stock.
Genocea Biosciences, Inc. Elects Not to Pursue Public Offering
Business Wire - Wed Jul 16, 10:30AM CDT
Genocea Biosciences, Inc. (NASDAQ:GNCA), a clinical-stage biopharmaceutical company developing T cell-enabled vaccines and immunotherapies, today announced that, due to market conditions, it has elected not to proceed at this time with its previously announced plans to pursue an underwritten public offering of 3,400,000 shares of its common stock.
Genocea Biosciences begins public offering of 3.4m common shares
M2 - Mon Jul 14, 8:55AM CDT
Biopharmaceutical company Genocea Biosciences (NasdaqGM:GNCA) disclosed on Monday the start of its public offering of 3,400,000 shares of its common stock.
Genocea Biosciences, Inc. Commences Public Offering of Common Stock
Business Wire - Mon Jul 14, 6:30AM CDT
Genocea Biosciences, Inc. (NASDAQ:GNCA), a clinical-stage biopharmaceutical company developing T cell-enabled vaccines and immunotherapies, today announced that it has commenced an underwritten public offering of 3,400,000 shares of its common stock. All the shares in the offering will be sold by Genocea.
Genocea Announces Positive Top-Line 12-Month Follow-up Data from Phase 1/2a Clinical Trial for HSV-2 Immunotherapy GEN-003
Business Wire - Tue Jul 01, 7:01AM CDT
Genocea Biosciences, Inc. (NASDAQ:GNCA), a clinical-stage biopharmaceutical company developing T cell-enabled vaccines and immunotherapies, today announced positive top-line 12-month follow-up data from a Phase 1/2a study of GEN-003, the Company's immunotherapy candidate against herpes simplex virus type 2 (HSV-2). At 12 months after the final dose, in an analysis of an exploratory endpoint, the mean reduction in genital lesion rate was 42 percent below baseline for the best-performing 30 microgram dose group, indicating that GEN-003 may continue to provide a durable effect on genital lesions beyond the six months previously reported. GEN-003 remained safe and well tolerated. Genocea intends to explore additional dose combinations in its upcoming Phase 2 dose optimization study, which may identify a dose which further improves the magnitude or durability of effect of GEN-003.
Genocea Biosciences (GNCA) Jumps: Stock Rises 8.7% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Jun 23, 8:39AM CDT
Genocea Biosciences, Inc. (GNCA) was a big mover last session, as its shares rose nearly 9% on the day.
4 Stocks Breaking Out on Big Volume
at The Street - Mon Jun 23, 7:38AM CDT
These stocks rising on unusual volume are within range of triggering breakout trades.
Genocea Announces Positive Top-Line Phase 1 Results for Novel Universal Pneumococcus Vaccine Candidate GEN-004
Business Wire - Mon Jun 23, 7:01AM CDT
Genocea Biosciences, Inc. (NASDAQ:GNCA), a clinical-stage biopharmaceutical company developing T cell-enabled vaccines and immunotherapies, today announced positive top-line results from a Phase 1 study of GEN-004, an investigational vaccine candidate designed to prevent infections from all serotypes of pneumococcus (Streptococcus pneumoniae), a major cause of infectious disease-related death globally. The Phase 1 study met its safety, tolerability and immunogenicity goals, including measurable increases in the blood of T helper 17 (TH17) cells, a rare cell type that provides immunity at epithelial and mucosal surfaces. Based on these data, the Company plans to advance GEN-004 into a Phase 2a trial in the third quarter of 2014.
Genocea Biosciences, Inc. - Product Pipeline Review - 2014
PR Newswire - Tue Jun 17, 3:56PM CDT
Reportbuyer.com has added a new market research report:
Virology Publishes Genocea HSV-2 Antigen Discovery Paper
Business Wire - Tue Sep 16, 8:02AM CDT
Genocea Biosciences, Inc. (NASDAQ: GNCA), a clinical-stage biopharmaceutical company developing T cell-directed vaccines and immunotherapies, today announced that the peer-reviewed journal Virology has published a paper describing how Genocea used it's ATLAS(TM) platform to identify the herpes simplex virus 2 (HSV-2) antigens for its GEN-003 clinical program. The paper, titled "Identification of novel virus-specific antigens by CD4+ and CD8+ T cells from asymptomatic HSV-2 seropositive and seronegative donors," positively identified multiple viral antigens that are associated with naturally-induced protective CD4+ and CD8+ T cell responses, presenting possible targets for the development of new immunotherapies and prophylactic vaccines.
Genocea reports launch of Phase 2a trial for universal pneumococcal vaccine candidate GEN-004
M2 - Fri Sep 12, 7:58AM CDT
Biopharmaceutical company Genocea Biosciences (NasdaqGM:GNCA) announced on Thursday that it has started its Phase 2a trial of its universal vaccine candidate against pneumococcus, GEN-004.
Genocea Commences Phase 2a Trial for GEN-004, Universal Pneumococcal Vaccine Candidate
Business Wire - Thu Sep 11, 1:00PM CDT
Genocea Biosciences, Inc. (NASDAQ: GNCA), a clinical-stage biopharmaceutical company developing T cell-directed vaccines and immunotherapies, today announced the initiation of a Phase 2a trial for GEN-004, the Company's universal vaccine candidate against pneumococcus. The trial is designed to evaluate the effect of dosing with GEN-004 on the frequency, magnitude and duration of colonization by pneumococcus in the nasopharynx of healthy adults.
Genocea Appoints Kenneth Bate to its Board of Directors
Business Wire - Thu Sep 11, 11:30AM CDT
Genocea Biosciences, Inc. (NASDAQ: GNCA), a clinical-stage biopharmaceutical company developing T cell-directed vaccines and immunotherapies, today announced that Kenneth Bate has joined the company's board of directors. Mr. Bate will also serve as chairman of the company's Compensation committee and a member of the Audit committee.
Genocea Presents Phase 1 Immunology Data for Novel Pneumoccocus Vaccine at ICAAC
Business Wire - Sat Sep 06, 3:00PM CDT
Genocea Biosciences, Inc. (NASDAQ: GNCA), a biopharmaceutical company developing T cell-directed vaccines and immunotherapies, today presented data from a Phase 1 study of GEN-004, an investigational vaccine designed to prevent disease caused by all serotypes of pneumococcus (Streptococcus pneumoniae) The poster (G-291), titled "Safety and Immunogenicity of a Novel Lipidated Protein Subunit Streptococcus Pneumoniae vaccine," was presented at the 54th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) in Washington, DC.
HSV-2 Vaccine in Development: CBCD Congratulates Genocea Biosciences (GNCA)
PRWeb - Sun Aug 17, 1:46AM CDT
"Infected with HSV-2? The CBCD recommends taking Novirin or Gene-Eden-VIR." - Greg Bennett, CBCD
Genocea Reports Second Quarter 2014 Financial Results
Business Wire - Wed Aug 06, 7:01AM CDT
Genocea Biosciences, Inc. (NASDAQ:GNCA), a clinical-stage biopharmaceutical company developing T cell-enabled vaccines and immunotherapies, today reported recent corporate highlights and its financial results for the second quarter ended June 30, 2014.
Genocea to Announce Second Quarter 2014 Financial Results on August 6, 2014
Business Wire - Wed Jul 30, 7:01AM CDT
Genocea Biosciences, Inc. (NASDAQ:GNCA), a clinical-stage biopharmaceutical company developing T cell-enabled vaccines and immunotherapies, announced today that it will hold a conference call and live audio webcast on August 6, 2014 at 9:00 a.m. ET to discuss financial results for the quarter ended June 30, 2014. The presentation, hosted by Genocea president and chief executive officer Chip Clark and chief financial officer Jonathan Poole, will also provide an update on the company's recent progress and upcoming milestones.
Genocea HSV-2 Immunotherapeutic GEN-003 Elicits Significant, Durable T Cell Responses in Vaccinated Subjects
Business Wire - Tue Jul 22, 7:02AM CDT
Genocea Biosciences, Inc. (NASDAQ:GNCA), a clinical-stage biopharmaceutical company developing T cell-enabled vaccines and immunotherapies, today presented data from a Phase 1/2a study of GEN-003, the Company's investigational immunotherapy against HSV-2, demonstrating that the immunotherapy elicited T cell, IgG and neutralizing antibody responses that remained significantly above baseline for 12 months after treatment. The data were presented at the 39th Annual International Herpesvirus Workshop, being held July 19-23, 2014 in Kobe, Japan.
Genocea Commences Phase 2 Dose Optimization Trial for GEN-003 HSV-2 Immunotherapy
Business Wire - Mon Jul 21, 7:01AM CDT
Genocea Biosciences, Inc. (NASDAQ:GNCA), a clinical-stage biopharmaceutical company developing T cell-enabled vaccines and immunotherapies, today announced the start of a Phase 2 dose optimization trial for GEN-003, the Company's immunotherapy candidate against herpes simplex-type 2 (HSV-2).
Genocea Biosciences, Inc. (GNCA) in Focus: Stock Rises 7.52% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Jul 17, 7:44AM CDT
Genocea Biosciences, Inc. (GNCA) was a big mover last session, as the company saw its shares rise over 7% on the day.
Genocea Biosciences decides not to pursue public offering due to market conditions
M2 - Thu Jul 17, 5:34AM CDT
Biopharmaceutical company Genocea Biosciences (NasdaqGM:GNCA) said on Wednesday that it has elected not to proceed with its plans to pursue its public offering of 3,400,000 shares of its common stock.
Genocea Biosciences, Inc. Elects Not to Pursue Public Offering
Business Wire - Wed Jul 16, 10:30AM CDT
Genocea Biosciences, Inc. (NASDAQ:GNCA), a clinical-stage biopharmaceutical company developing T cell-enabled vaccines and immunotherapies, today announced that, due to market conditions, it has elected not to proceed at this time with its previously announced plans to pursue an underwritten public offering of 3,400,000 shares of its common stock.
Genocea Biosciences begins public offering of 3.4m common shares
M2 - Mon Jul 14, 8:55AM CDT
Biopharmaceutical company Genocea Biosciences (NasdaqGM:GNCA) disclosed on Monday the start of its public offering of 3,400,000 shares of its common stock.
Genocea Biosciences, Inc. Commences Public Offering of Common Stock
Business Wire - Mon Jul 14, 6:30AM CDT
Genocea Biosciences, Inc. (NASDAQ:GNCA), a clinical-stage biopharmaceutical company developing T cell-enabled vaccines and immunotherapies, today announced that it has commenced an underwritten public offering of 3,400,000 shares of its common stock. All the shares in the offering will be sold by Genocea.
Genocea Announces Positive Top-Line 12-Month Follow-up Data from Phase 1/2a Clinical Trial for HSV-2 Immunotherapy GEN-003
Business Wire - Tue Jul 01, 7:01AM CDT
Genocea Biosciences, Inc. (NASDAQ:GNCA), a clinical-stage biopharmaceutical company developing T cell-enabled vaccines and immunotherapies, today announced positive top-line 12-month follow-up data from a Phase 1/2a study of GEN-003, the Company's immunotherapy candidate against herpes simplex virus type 2 (HSV-2). At 12 months after the final dose, in an analysis of an exploratory endpoint, the mean reduction in genital lesion rate was 42 percent below baseline for the best-performing 30 microgram dose group, indicating that GEN-003 may continue to provide a durable effect on genital lesions beyond the six months previously reported. GEN-003 remained safe and well tolerated. Genocea intends to explore additional dose combinations in its upcoming Phase 2 dose optimization study, which may identify a dose which further improves the magnitude or durability of effect of GEN-003.
Genocea Biosciences (GNCA) Jumps: Stock Rises 8.7% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Jun 23, 8:39AM CDT
Genocea Biosciences, Inc. (GNCA) was a big mover last session, as its shares rose nearly 9% on the day.
4 Stocks Breaking Out on Big Volume
at The Street - Mon Jun 23, 7:38AM CDT
These stocks rising on unusual volume are within range of triggering breakout trades.
Genocea Announces Positive Top-Line Phase 1 Results for Novel Universal Pneumococcus Vaccine Candidate GEN-004
Business Wire - Mon Jun 23, 7:01AM CDT
Genocea Biosciences, Inc. (NASDAQ:GNCA), a clinical-stage biopharmaceutical company developing T cell-enabled vaccines and immunotherapies, today announced positive top-line results from a Phase 1 study of GEN-004, an investigational vaccine candidate designed to prevent infections from all serotypes of pneumococcus (Streptococcus pneumoniae), a major cause of infectious disease-related death globally. The Phase 1 study met its safety, tolerability and immunogenicity goals, including measurable increases in the blood of T helper 17 (TH17) cells, a rare cell type that provides immunity at epithelial and mucosal surfaces. Based on these data, the Company plans to advance GEN-004 into a Phase 2a trial in the third quarter of 2014.
Genocea Biosciences, Inc. - Product Pipeline Review - 2014
PR Newswire - Tue Jun 17, 3:56PM CDT
Reportbuyer.com has added a new market research report:
